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One Sentence Summary:  
We report here that, in addition to its role in the induction of Th17 cell development, ongoing 
classic IL-6 receptor signaling is indispensable for maintenance of the Th17 program, identifying 
a major mechanism by which Th17 cells are retained despite their tendency to transdifferentiate 
into Th1-like cells that drive immune-mediated disease. 
 
Abstract:  
Acting in concert with TGF-b, IL-6 signaling induces Th17 cell development by programming 
Th17-related genes via STAT3. A role for IL-6 signaling beyond the inductive phase of Th17 cell 
development has not been defined, as IL-23 signaling downstream of Th17 cell induction also 
activates STAT3 and is thought responsible for Th17 cell maintenance. Here, we find that IL-6 
signaling is required for both induction and maintenance of Th17 cells; IL-6Ra–deficient Th17 
cells rapidly lost their Th17 phenotype and did not cause disease in two models of colitis. Co-
transfer of WT Th17 cells with IL-6Ra–deficient Th17 cells induced colitis but was unable to 
rescue phenotype loss of the latter. High IL-6 in the colon promoted classic, or cis, rather than 
trans receptor signaling that was required for maintenance of Th17 cells. Thus, ongoing classic IL-
6 signaling underpins the Th17 program and is required for Th17 cell maintenance and function. 
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Main Text:  
Introduction 
Distinct subsets of effector CD4+ T cells differentiate from multipotent naïve precursors under 
control of antigen- and cytokine-induced signals. Th17 cells arise from antigen-activated naïve 
CD4+ T cells in response to TGF-b and IL-6 (1-4), the latter inducing a signaling cascade that 
recruits Janus kinases JAK1, JAK2 and TYK2. These in turn induce tyrosine phosphorylation of 
both STAT3 and STAT1 (5). STAT3 induces the expression of Th17-related genes including 
Il17a, Il17f, Il22, Il23r and the master transcription factor Rorc (6-8), which itself is a positive 
regulator of key Th17 genes and a negative regulator of alternative lineage fates (9-12). Expression 
of Il23r as well as other Th17-specific genes is required for several Th17-mediated diseases, 
including inflammatory bowel disease (IBD) (13-15), psoriasis (16) and ankylosing spondylitis 
(17), and exposure of Th17 cells to IL-23 is critical for Th17 maintenance and pathogenesis (15, 
18-22).  
Th17 cells are highly plastic (19, 23). Under the influence of IL-12 most Th17 cells rapidly 
extinguish RORgt expression up-regulate T-bet and a Th1-like program (19, 24, 25). Although IL-
23 has been shown to important for Th17 cell maintenance due to its activation of STAT3, 
reiterative IL-23 signaling also induces Th17 cells to extinguish Il17a and Rorc in favor of Th1-
related genes (19, 24, 25). This transdifferentiation of Th17 cells is dependent on both STAT4 and 
T-bet (19, 23, 26, 27). Thus, the balance of cytokines in the local environment play a critical role 
in Th17 maintenance and function. Although the role of IL-6 in Th17 cell induction is well 
characterized (2, 4), it is unknown whether ongoing IL-6 signaling contributes to Th17 
maintenance, or whether there are additional factors that antagonize lineage-destabilizing signals 
such as IL-12– and IL-23–induced STAT4 to preserve the Th17 phenotype.  
IL-6 is produced by a wide range of cells, including hematopoietic-derived monocytes, 
macrophages and dendritic cells, and non-hematopoietic stromal cells such as fibroblasts and 
endothelial cells(28). Various inflammatory cytokines (e.g., IL-1 and TNFa) and innate sensing 
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mechanisms contribute to the generation of IL-6, which elicits a broad range of biological 
functions on target cells (29). Effects range from control of organ development, the regulation of 
the acute-phase response and immune-related functions such as cell survival, differentiation, 
proliferation and apoptosis (30). The pleiotropic effects of IL-6 are transmitted through a tightly 
controlled, variable mode of signaling (31). Classic, or cis, IL-6 receptor signaling occurs in cells 
that express both membrane-bound IL-6Ra and the signal transducing component, gp130, which 
bind IL-6 in a hexameric complex where IL-6, IL-6Ra and gp130 exist in a 2:2:2 stoichiometry 
(32). While gp130 is ubiquitously expressed (33), IL-6Ra expression is restricted to hepatocytes 
(34) and subsets of leukocytes, including naïve T cells (35). In activated cells that express IL-6Ra, 
particularly activated neutrophils, monocytes and T cells (36), the extracellular domain can be 
shed by proteolysis to liberate a functional soluble IL-6Ra (sIL-6Ra)(37, 38). Soluble IL-
6Ra binds IL-6 to form an agonistic dimer that can bind gp130 to induce IL-6 signaling through a 
mechanism termed IL-6 trans-signaling. A soluble isoform of gp130 (sgp130) buffers the activity 
of IL-6 trans-signaling and restricts the bioavailability of IL-6–sIL-6Ra complexes for signaling 
through membrane-bound gp130 (39). Given that gp130 is ubiquitously expressed, the local 
balance between IL-6, sIL-6Ra and sgp130 IL-6 responsive target cells thus determines the 
prominent mode of IL-6 signaling acting on any cell type (40). A additional form of IL-6 signaling, 
referred to as trans-presentation, involves binding of the cell suface-asscociated IL-6–sIL-6Ra 
complexes on a subset of dendritic cells to gp130 expressed on naive T cells, and has been 
proposed as a mechanism that promotes the development of pathogenic Th17 cells (41). 
An excess of IL-6 relative to sIL-6Ra in acute injury leads to classic signaling, which is 
believed to have more homeostatic effects such as the acute phase response (42). An excess of sIL-
6Ra, however, is a marker of active inflammation (43) and allows for trans-signaling to a wide 
variety of cell targets, and amplifies inflammatory responses through the recruitment and 
activation of mononuclear cells (44, 45). IL-6 trans-signaling has been shown to affect the 
recruitment of Th17 cells in model of peritoneal inflammation (46), although it is unknown 
whether these effects were direct or indirect. 
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Here, we have used a mouse model of Th17 cell-induced colitis (19) to examine a possible 
contribution of IL-6 to Th17 biology beyond the early phase of Th17 induction. We find that 
expression of IL-6Ra by mature Th17 cells is indispensable for maintenance of the Th17 
phenotype and a pathogenic response. Classic IL-6 receptor signaling was dominant over IL-6 
trans-signaling in the colon due to the high levels of IL-6 produced there. Our findings establish 
that ongoing IL-6 is required for maintenance of Th17 cells and suggest that a major contributor 
to Th17 plasticity is the loss of IL-6 signaling. 
 
Results  
Naïve CD4+ T cells require IL-6 signaling for development of colitis 
The Th17 pathway is critical to IBD pathogenesis. In view of the requirement for IL-6 in Th17 
cell development, we examined whether naïve CD4+ T cells deficient in IL-6Ra were able to 
develop into Th17 cells and drive intestinal inflammation in vivo. WT and Il6ra-/- naïve T cells 
were used as donors in the CD4+ CD45RBHi T cell transfer colitis model (47). Eight weeks after 
transfer into Rag1-/- recipients, T cells from WT mice were found to induce substantial disease. 
This was reflected by a significant loss of weight (Fig. 1A), as well as an increase in CD4+ cells 
recovered from the colonic lamina propria (CLP) of colitic mice (Fig. 1B). While the transfer of 
WT CD4+ cells resulted in pronounced pathology (Fig. 1C and D), the transfer of Il6ra-/- CD4+ cells 
failed to induce weight loss or significant colonic inflammation.  
Consistent with previous reports, flow cytometric analysis of T cells recovered from the 
inflamed CLP and mesenteric lymph node (MLN) identified four populations of IL-17A and IFN-
g expressing cells in WT recipients (Fig. 1G and Supplementary Fig. 1)(19). In contrast, there 
was a significant reduction in the percentage and number of IL-17A+ and IL-17A+IFN-g+ cells in 
the CLP (Fig. 1G,H) and MLN (Supplementary Fig. 1) of recipients of Il6ra-/- T cells. 
Interestingly, the relative percentage of IFN-g producing cells in Il6ra-/- recipient T cells was 
unchanged in the CLP (Fig. 1H) and increased in the MLN (Supplementary Fig. 1), but their 
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numbers were not increased. Thus, IL-6 receptor signaling in these cells is not required for 
development of an intact Th1 pathway but is essential for control of pathogenic T cells displaying 
a Th17 program (15, 48). The numbers of CD4+ Foxp3+ cells in the CLP (Fig. 1E,F) and MLN 
(Supplementary Fig. 1) remained unchanged between recipients of WT and Il6ra-/- cells, 
suggesting that reduction in disease in Il6ra-/- recipients was not due to an increase in Treg cells 
and suppression of an inflammatory response in the absence of IL-6. Together, these results 
indicate that IL-6 signaling in naïve CD4+ T cells is required for the pathogenesis of IBD and that 
trans-signaling in the absence of membrane bound IL-6Ra is not sufficient to induce development 
of a pathogenic Th17 response. These findings are in agreement with other studies that showed 
defective Th17 responses in the absence of IL-6Ra (49).  
 
Maintenance and pathogenesis of Th17 cells is dependent on ongoing IL-6 signaling 
Previous results using IL-6–deficient animals or blocking IL-6 interventions suggest that IL-6 is 
required to promote Th17-induced disease (12, 50, 51). However it is currently unknown whether 
on-going IL-6 signaling is required to maintain Th17 responses. To investigate this, we used a 
Th17 transfer model of colitis (19), wherein Th17 polarized cells are cultured ex vivo from naïve 
CD4+ T cells of Il17fThy1.1 reporter mice (Fig. 2A) and sorted on the basis of Thy1.1 (IL-17F) 
expression (Fig. 2B). Transfer of Thy1.1+ (IL-17F+) Th17 cells into Rag1-/- mice induces a rapid 
onset of disease that is equivalent in severity to that caused by transfer of CD4+ CD45RBHi T cells 
(19).  
Isolated Th17 cells were transferred into groups of Rag1-/- or Il6-/-.Rag1-/- mice. When compared 
to Il6-/-.Rag1-/- recipients, Rag1-/- recipients showed significantly elevated disease activity (Fig. 2C, 
D). In this regard, the absence of IL-6 lead to a reduction in the percentage and number of IL-17A+ 
CD4+ cells recovered from the CLP of colitic mice (Fig. 2E, F). However, the percentage and 
numbers of double IL-17A+IFN-g+ and single IFN-g+ cells in Il6-/-.Rag1-/- recipients was comparable 
to that seen in Rag1-/- recipients. The percentage of CD4+ Foxp3+ cells in the CLP of recipient mice 
was also unchanged (Supplementary Fig. 2), suggesting that disease disparity was not due to 
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elevated Treg numbers in the absence of IL-6. While IL-6 signaling is known to promote anti-
apoptotic mechanisms (44), Annexin V staining of CD4+ cells recovered from the CLP of colitic 
Rag1-/- and Il6-/-.Rag1-/- recipients showed no difference in the percentage of apoptotic (Annexin V+ 
Propidium Iodide+) cells (Supplementary Fig. 2), suggesting that the differences observed was 
not due to a loss of IL-6-mediated T cell survival at this stage of disease. While IL-6 deficient mice 
are known to have other defects that may inhibit an immune response, particularly in the innate 
immune compartment, these findings support a role for IL-6 in the maintenance of Th17 responses 
required for chronic disease progression. We therefore considered the mode of IL-6 receptor 
signaling responsible for this outcome. 
 
Classic IL-6 signaling is required for maintenance of pathogenic Th17 cells 
The previous experiments suggested that ongoing IL-6 signaling is required to maintain a 
pathogenic Th17 response, but could not discern whether IL-6 was acting via classic versus trans 
IL-6 signaling to maintain Th17 cells. Because naïve CD4+ T cells from Il6ra-/- mice are not 
responsive to direct IL-6 activation (Fig. 3A), we used Th17 cells from Il6ra-/- mice as donors in 
the Th17 transfer colitis model to interrogate the requirement for classic IL-6 receptor signaling. 
Consistent with our previous work (46), under Th17 polarizing conditions, Il6ra-/- CD4+ T cells 
could not produce IL-17A in response to TGF-b + IL-6. However, this lack of IL-6–induced Th17 
differentiation was restored by using a recombinant IL-6-sIL–6Ra fusion protein (Hyper-DS-sIL-
6R; HDS), which acts exclusively via IL-6 trans-signaling (Fig. 3B). Importantly, both IL-6 and 
HDS generated a similar proportion of Th17 cells when combined with TGF-b (Fig. 3B, 
Supplementary Fig. 3). There was no difference in the proliferative capacity of WT and Il6ra-/- 
Th17 cells in vitro as measured by vital dye dilution, and RNA-seq analysis of WT (IL-6), WT 
(HDS), and Il6ra-/- Th17 precursors showed a very high degree of similarity by principal component 
analysis of gene expression, with only 3 genes being > 1.5 fold differentially expressed with an 
FDR of < 0.05 (Serpine2, Kit, Nav1) (Supplementary Fig. 3). In addition, pSTAT3 levels were 
equivalent between Th17 cells restimulated with IL-6 or HDS in vitro (Supplementary Fig. 3). 
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Thus, naïve CD4+ T cells display a comparable capacity to differentiate into Th17 cells in response 
to either classic or trans IL-6 receptor signaling. 
Exploiting this dual form of Th17 cell regulation, we next considered the relative importance 
of these IL-6 receptor signaling mechanisms in maintaining local Th17 responses. Thy1.1+ Th17 
precursors from WT (IL-6 polarized), WT (HDS polarized) and Il6ra-/- (HDS polarized) CD4+ T-
cells were transferred into Rag1-/- mice. Disease activity and T cell phenotype were assessed four 
weeks after transfer. Notably, while Th17 cells from WT mice caused severe disease in Rag1-/- 
recipients, Th17 cells from Il6ra-/- mice induced significantly less pathology (Fig. 3C, 
Supplementary Fig. 3). Importantly, there was no difference in the ability of WT (IL-6) versus 
WT (HDS) Th17 cells to induce disease, suggesting that these cells are functionally comparable. 
The reduced disease observed in recipients of Il6ra-/- Th17 cells was associated with a significant 
loss of IL-17A+ and IL-17A+IFN-g+ T cells recovered from the CLP, with a concomitant increase in 
the percentage of IFN-g+ T cells when compared to recipients of WT Th17 cells (Fig. 3E,G). As 
with disease scores, there were no detectable differences between phenotypes of recovered CD4+ 
cells from WT (IL-6) and WT (HDS) recipients. Thus, in the absence of IL-6 sustained signaling, 
Th17 cells were unstable, indicating that ongoing, classic IL-6 signal is required to maintain a 
Th17 response.  
Additionally, there were no differences in the percentage or number of CD4+ Foxp3+ cells in 
the CLP of Il6ra-/- versus WT recipients (Fig. 3F,H-I), suggesting that loss of Th17 phenotype is 
not due to conversion to Treg in the absence of IL-6 signaling. Serum sIL-6Ra, which is elevated 
during inflammation due to shedding from membrane bound IL-6Ra–expressing cells, was 
significantly increased in recipients of WT Th17 cells. This was in contrast to recipients of Il6ra-/- 
Th17 cells (Fig. 3D), in which serum sIL-6Ra levels were equivalent to untreated Rag1-/- mice, 
suggesting that sIL-6Ra is a marker of disease activity in this model. Importantly, colon explant 
cultures showed a significant reduction in IL-17A in Il6ra-/- Th17 cell recipients, despite showing 
an increase in IL-23 and IL-21 levels (Supplementary Fig. 3), suggesting that these STAT3 
inducing cytokines were present but unable to compensate for the loss of IL-6 responsiveness in 
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CD4+ cells. Together, these results suggest that continued classic IL-6 receptor signaling, rather 
than IL-6 trans-signaling is required to maintain the pathogenic phenotype of Th17 cells in vivo, 
and that the Th17 phenotype is unstable in the absence of classic signaling.  
 
Loss of Th17 phenotype in Il6ra-/- mice cannot be rescued by co-transfer of WT Th17 cells 
Coordinate increases of sIL-6Ra and IL-6 potentiate IL-6 trans-signaling. To rule out the 
possibility that reduced disease in recipients of Il6ra-/- Th17 cells (Fig. 3C) was due to lack of 
availability of sIL-6Ra, co-transfer experiments were performed to assess the ability of Il6ra-/- 
Th17 cells to maintain their phenotype in the presence of inflammation induced by WT Th17 cells. 
Th17 precursors from congenically marked WT and Il6ra-/- mice were transferred into Rag1-/- 
recipients either individually or together (WT + Il6ra-/- 4 wks), with a fourth group receiving Il6ra-
/- Th17 cells 2 weeks after WT Th17 cell transfer (WT + Il6ra-/- (2 wks)) (Fig. 4A).  
Four weeks after initial transfer, WT and Il6ra-/- Th17 cells in recipients of both (WT + Il6ra-/- 
4 wks) had repopulated the colon in equivalent numbers (Supplementary Fig. 4), suggesting there 
was no survival advantage by population. Disease severity trended with the total number of 
recovered CLP CD4+ T cells (Supplementary Fig. 4). For example, disease was significantly 
ameliorated in Rag1-/- mice that received single Il6ra-/- Th17 cell transfers when compared to 
recipients of WT Th17 cells (Fig. 4B, Supplementary Fig. 5). Both co-transfer groups developed 
disease that was equivalent to WT recipients, reflecting the increased total number of pathogenic 
CD4+ T cells in these mice. CD4+ T cells recovered from the CLP of recipient mice showed that 
regardless of whether they were transferred individually or with WT cells, Il6ra-/- Th17 cells failed 
to retain their Th17 identity, as evidenced by a significant reduction in the percentage of IL-17A+ 
and IL-17A+IFN-g+, as well as IL-17A+TNF-a+ and IL-17A+GM-CSF+ CD4+ T cells compared to 
recipients of WT cells (Fig. 4C-D and Supplementary Fig. 4). This correlated with a significant 
reduction in the numbers of IL-17A+ and IL-17A+IFN-g+ T cells recovered from the majority of 
Il6ra-/- transfer recipients (Fig. 4C).  
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Importantly, loss of the Th17 phenotype by Il6ra-/- cells occurred as early as 2 weeks post 
transfer (Fig. 4D, bottom panel, and Supplementary Fig. 4). And while the percentage of IFN-
g+ cells was increased (and IL-17A+ cells lost) in the CLP of Il6ra-/- Th17 cell recipients in both co-
transfer groups, the number of IFN-g+ cells was significantly decreased compared to WT cells in 
all groups except that of WT + Il6ra-/- cell recipients (4 wks).  
The balance between classic IL-6 receptor signaling and IL-6 trans-signaling is tightly 
controlled by the bioavailability of IL-6, sIL-6Ra and sgp130. These were therefore quantified in 
serum and colon explant cultures from recipient mice (Supplementary Fig. 4). Significant 
differences were found: Molar ratios of each analyte showed that systemic sIL-6Ra was in excess 
of both IL-6 and sgp130 in all recipient groups (Fig. 4E-F)—a stoichiometry that favors IL-6 trans-
signaling. Conversely, colon explant cultures showed that IL-6 was in molar excess relative to sIL-
6Ra in all groups (Fig. 4E), while sIL-6Ra was again in excess of sgp130 (Fig. 4F)—enabling 
both classic and trans-signaling in the colon microenvironment.  
IL-6 signaling promotes T cell proliferation and inhibits apoptosis via its actions to increase 
Bcl-2(52). We therefore measured cell cycling in WT and Il6ra-/- Th17 cells following transfer. 
There were no differences in either BrdU+ or Ki67+ T cells isolated from the spleens and MLNs 
(Supplementary Fig. 5) of recipient Rag1-/- mice 7 days after transfers of WT, Il6ra-/- or co-
transferred WT + Il6ra-/- Th17 cells. From this we inferred that there was no difference in the 
proliferative capacity of Il6ra-/- Th17 cells, whether transferred individually or co-transferred with 
WT Th17 cells. Similarly, there were equivalent percentages of CD4+ T cells from the CLP and 
MLN (Supplementary Fig. 5) that were BrdU+ and Ki67+ four weeks after transfer, suggestive of 
no defect in the proliferative capacity of Il6ra-/- Th17 cells in active colitis. Interestingly, nearly 
70% of CLP T cells from Il6ra-/- Th17 recipients were BrdU+ four weeks after transfer, even though 
these cells were not pathogenic. Immunofluorescent staining of colon sections from WT + Il6ra-/- 
recipients showed that WT and Il6ra-/- Th17 cells repopulate the colon equivalently at 4 weeks post 
transfer (Fig. 4G-H), indicating no defect in the ability of Il6ra-/- Th17 cells to traffic to the colon. 
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Together, these findings establish that persistent IL-6 signaling is required to maintain the 
Th17 phenotype in vivo, and that classic rather than trans IL-6 receptor signaling is favored for 
maintenance of the Th17 program in the colon microenvironment; the requirement for IL-6 
signaling is not related to effects on cell cycle or cell survival, but instead appears to be intrinsic 
to Th17 lineage maintenance. 
 
IL-6 trans-signaling activates STAT1 and STAT3 in IL-6Ra-deficient Th17 cells ex vivo 
IL-6 signaling activates the transcription factors STAT3 and STAT1 in naive CD4+ T cells, and 
studies have shown that CD4+ T cell activation status can alter the balance of STAT3/STAT1 
activation downstream of IL-6 signaling (53, 54). Il6ra-/- Th17 cells appeared to be either 
unresponsive or unable to receive IL-6 trans-signaling in vivo (Fig. 4). To determine whether this 
might be due to a lack of inflammation-driven availability of the IL-6–IL-6Ra complex or 
unresponsiveness of Th17 cells to this complex, we co-transferred congenically marked Thy1.1+ 
Th17 cells from WT and Il6ra-/- mice into Rag1-/- recipients. Four weeks after transfer, we examined 
the responsiveness of recovered MLN T cells to IL-6 or HDS ex vivo.  
Overall, responsiveness to IL-6 signaling was lower in ex vivo T cells compared to naïve T 
cells (Fig. 5A,B), due at least in part to reduced expression of IL-6Ra and gp130 on recovered 
cells (Supplementary Fig. 6). IL-6 trans-signaling mediated by HDS induced both pY-STAT3 
(Fig. 5A,B) and pY-STAT1 (Fig. 5C,D) in a small but significant fraction of both WT and Il6ra-/- 
T cells stimulated ex vivo, although the percentage of cells positive for pY-STAT3 was 
substantially higher than those positive for pY-STAT1. In contrast, only WT CD4+ T cells were 
responsive to classic IL-6 signaling ex vivo. IL-6 stimulation induced pY-STAT3 in a significant 
fraction of WT cells, but, interestingly, did not induce pY-STAT1 in the same population, 
indicating that, unlike naïve precursors, coupling of the IL-6 receptor to STAT1 via classic 
signaling is lost in Th17 cells.  
Collectively, these data show that both WT and Il6ra-/- CD4+ T cells are responsive to trans-
signaling ex vivo, but this is limited by diminished gp130 expression, consistent with activation-
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induced downregulation of gp130 in CD4+ T cells (53, 55, 56). Moreover, classic IL-6 receptor 
signaling in WT cells, which promotes retention of the Th17 phenotype, preferentially induces pY-
STAT3 without pY-STAT1. Therefore, ongoing classic IL-6 signaling in Th17 cells is required to 
maintain tyrosine phosphorylation of STAT3, and thus IL-6-induced STAT3 activation is critical 
for both the development and maintenance of Th17 cells. 
 
Maintenance of the Th17 transcriptional program is dependent on ongoing IL-6 receptor 
signaling 
To further characterize the phenotypic divergence of Il6ra-/- Th17 cells, we performed RNA-
sequencing analysis of T cells that were isolated from the CLP of Rag1-/- mice that received co-
transfers of congenically marked WT and Il6ra-/- Th17 cells (Fig. 6A). Recipient mice were 
repopulated with equivalent percentages (Fig. 6B) and numbers (Fig. 6C) of Th17 cells in the CLP 
four weeks after transfer. Transcriptome analysis revealed a number of differences in gene 
expression in recovered WT and Il6ra-/- CD4+ T cells ex vivo (Fig. 6D). Gene set enrichment 
analysis (GSEA) using a previously defined Th17–Th1 gene set (57) identified significant 
enrichment of Th1-related genes in Il6ra-/- T cells ex vivo (Fig. 6E, right and Supplementary Fig. 
7). Conversely, and in accord with our previous findings, the transcriptome of WT T cells was 
enriched for a subset of genes related to Th17 cells ex vivo (Fig. 6E, left and Supplementary Fig. 
7). Signature Th17 related genes that were retained in WT but not Il6ra-/- T cells ex vivo included 
Il17a, Il17f, Il21, Il22, Il23r, Rorc and Ccr6 (Fig. 6F). A number of Th1-related genes was 
enriched in Il6ra-/- T cells, including Ifng, Tbx21 and Il12rb2, indicative of a molecular program 
more similar to Th1 cells than the Th17 precursors. GSEA using a dataset derived from colonic 
CD4+ T cells (GSE58147)(58) showed the expression pattern of WT and Il6ra-/- CD4+ T cells was 
significantly related to that of WT and Il23r-/- CD4+ T cells, respectively (Supplementary Fig. 7). 
Likewise, a subset of genes induced by Tbx21 was significantly associated with Il6ra-/- T cells 
(Supplementary Fig. 7), consistent with the transdifferentiation of these cells to a Th1-like 
program.  
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Using a previously published dataset defining the transcriptional program of Th17 cells (9), 
significant enrichment of Stat3- and Rorc-induced genes was found in WT T cells ex vivo, as 
expected, whereas Stat3- and Rorc-repressed genes were significantly enriched in Il6ra-/- T cells 
(Fig. 6G-J). In addition, expression of genes regulated by other transcription factors associated 
with the Th17 lineage, including Batf, Irf4, Fosl2 and Hif1a, was significantly reversed in Il6ra-/- 
T cells ex vivo (Supplementary Fig. 7), in fitting with the loss of Th17 phenotype in these cells. 
As expected, the Stat3- and Rorc-induced genes enriched in WT cells contained some overlap, 
including Il17a, Il17f, Il23r, Il1r1 and Lif (Fig. 6H,J). Interestingly, there was little overlap in 
genes repressed by Stat3 and Rorc in Il6ra-/- CLP T cells. Targets of Rorc included Ahr, Ccr5 and 
Il12rb2 (Fig. 6H), while Stat3 repressed genes included Fasl, and the Th1-related transcription 
factors Tbx21 and Irf1 (Fig. 6J). This is consistent with data suggesting that Stat3 is a key 
transcriptional activator in Th17 cells, whereas Rorc is thought to be an expression modulator (9).  
Our previous work has shown that Th17 cells develop divergent gene expression profiles under 
the influence of IL-23 signaling (19), such that an increase in expression of Tbx21, Ifng, Ccr5 and 
Fasl is correlated with a significant portion of IFN-g–producing ex-Th17 cells, whilst a decrease 
in the expression of Il17a, Il17f, Ccr6 and Ccl20 is correlated with a reduction in IL-17A+ Th17 
cells. We find here that Il6ra-/- CLP CD4+ T cells were enriched for the aforementioned Th1 genes. 
Conversely, expression of Th17-related genes was associated with WT, rather than Il6ra-/- CLP 
CD4+ T cells, further indicating that ongoing IL-6 signaling is required to maintain Th17 program 
stability. Taken together, these data confirmed our finding that Il6ra-/- Th17 cells rapidly lose their 
Th17 phenotype in vivo, and extended them to show that, absent classic ongoing IL-6 signaling, 
the entire Th17 gene expression program is downregulated, favoring the transition of many cells 
to a Th1-like program. 
 
Enforced RORgt expression in IL-6R-deficient Th17 cells supports maintenance of the Th17 
program but does not completely prevent Th1 transdifferentiation  
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A critical gene target of IL-6 signaling in Th17 cells is Rorc, which underpins the Th17 gene 
expression program while inhibiting alternative programs. Important functions of IL-6/STAT3-
induced RORgt include inhibition of IFN-g/STAT1 and IL-12/STAT4 via suppression of T-bet 
(61), although RORgt also sustains expression of Il23r, which has been shown to be central to the 
transdifferentiaiton of Th17 cells into Th1-like cells in vivo via STAT4 signaling (19, 26, 73). Our 
gene expression analysis showed that in IL-6Ra-deficient Th17 cells, Rorc and Il23r expression 
were rapidly lost along with other genes of the Th17 program following adoptive transfers (Fig. 
6F). To determine whether loss of RORgt was responsible for loss of the Th17 phenotype, we 
polarized congenically marked naïve WT and Il6ra-/-.Il17fThy1.1 T cells under Th17 conditions with 
HDS and transduced cells with retroviruses that expressed GFP alone or GFP plus RORgt at 24 
hrs of a 5 day culture (Fig. 7A). As expected, Th17 precursors from both WT and Il6ra-/- mice 
expressed a higher percentage of IL-17A after enforced RORgt expression (Fig. 7B, right). 
GFP+Thy1.1+ Th17 cells were sorted 4 days after transduction and WT Th17 cells expressing GFP 
alone (WT pMIG) were transferred together with either Il6ra-/- cells expressing GFP alone (Il6ra-/-  
pMIG) or Il6ra-/-  cells expressing both GFP and RORgt (Il6ra-/-  pMIG-RORgt) into Rag1-/- 
recipients.  
Three weeks after transfer, both co-transfer groups had developed comparable disease (Fig. 7C, 
7F). CD4+ T cells recovered from the CLP showed that, consistent with previous results (Fig. 4), 
Th17 cells transfected with empty vector (Il6ra-/- pMIG) rapidly lost their Th17 phenotype as shown 
by a significant reduction in IL-17A+ cells compared to co-transferred WT (WT pMIG) Th17 cell 
controls (Fig. 7D and E), with a concomitant increase in the relative frequency of IFN-g+ cells. In 
contrast, Il6ra-/- Th17 cells transfected with RORgt (Il6ra-/- pMIG-RORgt) had a much greater 
propensity to retain their Th17 phenotype even in the absence of classical IL-6 signaling. Thus, 
the frequencies of both IL-17A+ and IL-17A+ IFN-g+ cells from recipients of RORgt-transfected 
Il6ra-/- Th17 cells were markedly increased in comparison to those transduced with vector alone 
(Fig. 7D and E). Moreover, RORgt-transfected Th17 cells had significantly greater retention of 
IL-17 expression compared to WT controls, reflecting the role of RORgt in promoting Th17 
Harbour et al. 
 15 
cytokine production (12). Interestingly, although RORgt-transfected Il6ra-/- Th17 cells had 
significantly decreased expression of IFN-g compared to Il6ra-/- Th17 cells transfected with empty 
vector, they showed a modest, but significant increase in the fraction of IFN-g+ cells compared to 
WT Th17 cells. This is consistent with the development of Th1-like cells from the larger frequency 
of Th17 precursors maintained by exogenous RORgt (19), but also suggested that enforced RORgt 
expression did not entirely repress transdifferentiation of Th17 cells into Th1-like cells.  
In accord with the phenotypic data, gene expression analysis of CD4+ T cells recovered from CLP 
showed that RORgt-transfected Il6ra-/- Th17 cells had a significant increase in expression of genes 
of the Th17 program compared to empty-vector Il6ra-/- Th17 cells, including Il17a, Rorc, Il17f and 
Il23r (Fig. 7G). Further, there was decreased Il12rb but not Tbx21, suggesting differential 
sensitivities of these two genes to RORgt-mediated repression. Notably, expression of Rorc was 
not significantly increased over that of recovered WT controls, indicating the levels of RORgt 
driven by retroviral transduction were physiologic. As anticipated, Il23r was significantly elevated 
in RORgt-transfected Il6ra-/- Th17 cells compared to both empty-vector Il6ra-/- cells and co-
transferred WT control cells, consistent with an central role for IL-6–induced RORgt in the 
maintenance of Il23r expression. As IL-23 signaling via STAT4 is known to be a principal pathway 
mediating the transdifferentiation to Th1-like cells in vivo (19, 26), it is likely that the elevated 
expression of IL-23R by RORgt-transfected Il6ra-/- Th17 cells contributed to the modest increase in 
expression of IFN-g by these cells compared to WT controls, despite on-going RORgt expression. 
Together, these results suggest that ongoing classical IL-6 signaling supports the Th17 program 
by sustaining RORgt expression that contributes to the maintenance of Th17 cells, which provide 
a reservoir of cells that can transdifferentiate into pathogenic Th1-like cells that are essential to 
colitogenesis. 
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Discussion  
IL-6 is required for lineage specification of Th17 cells through its activation of STAT3, which 
antagonizes the IL-2/STAT5-driven specification of induced Treg cells with which Th17 cells 
share TGF-b–dependent developmental programming (62-64). Here, we report that in addition to 
its key role in Th17 cell induction (3, 4), there is an absolute requirement for persistent IL-6 
signaling to maintain the Th17 genetic program, and thus Th17 cells. Although it has been reported 
that IL-23 signaling is important for the maintenance of Th17 cells (18, 19, 21), we find that 
ongoing IL-6 signaling is indispensable and foundational, acting upstream of IL-23 via its unique 
function to sustain RORgt expression and thereby IL-23R expression. Importantly, although Th17 
cells were fully competent to receive IL-6 trans-signaling, classic IL-6 signaling proved necessary 
for Th17 maintenance in the uninflamed and inflamed intestines. This appears to be due to the 
combined effects of high local production of IL-6, which was incompletely buffered by soluble 
IL-6Ra, and the abundance of gp130-expressing non-T cells (e.g.., intestinal epithelial cells), 
which act as a sink for trans-signaling. Possible differences between the classic and trans-signaling 
modes may also be contributory and deserve further study.  
In contrast to Th1 and Th2 cells, Th17 cells show substantially greater plasticity (19, 23, 65). 
This reflects intrinsic instability in the transcriptional circuit upon which Th17 cell development 
is based. Whereas the Th1 and Th2 programs are reinforced by cell-extrinsic and -intrinsic 
mechanisms that enhance expression of T-bet and GATA-3, respectively(66), mechanisms by 
which RORgt expression is sustained and the Th17 program maintained have been unclear. IL-23 
has been reported to be a trophic factor for Th17 cells (19, 23, 65), but IL-23 signaling also 
promotes the transdifferentiation of Th17 cells to Th1-like cells (19, 26), thereby contributing to 
the instability of Th17 cells. Despite its dominant activation of STAT3, IL-23 signaling also 
activates STAT4, leading to expression of T-bet, which represses RORgt via direct binding to the 
Rorc locus (26, 61). Our finding that Th17 cells require tonic or intermittent classic IL-6 signaling, 
which shifts from a STAT3–STAT1 output during early development to a pure STAT3 output in 
mature cells, indicates that this pathway of STAT3 activation may be essential to counterbalance 
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the STAT4 output of the IL-23 (or IL-12) receptor to sustain RORgt and the Th17 program. 
However, it also appears that the IL-6–dependent maintenance of a pool of Th17 cells provides 
precursors from which pathogenic Th1-like cells can arise. In view of the findings herein, it would 
appear that stable expression of RORgt does not completely block Th1 reprogramming, consistent 
with a dominant role of T-bet in overriding the Th17 program.  
In view of the role for STAT1 in modulating the STAT3-dominant output of the IL-6 receptor 
via formation of STAT3-STAT1 heterodimers (67), results herein suggest that the maintenance of 
mature Th17 cells via classic signaling may be strictly dependent on STAT3 homodimers. 
Moreover, as STAT1 signaling impairs Th17 programming (59), the loss of STAT1 activation in 
Th17 cells receiving classic IL-6 signaling may further reinforce maintenance of the Th17 
program. Because trans IL-6 signaling in Th17 cells retained a STAT1 output, which can also 
induce T-bet expression, it is possible that Th17 cells exposed to this mode of IL-6 signaling may 
be less resistant to transdifferentiaion mediated by Th1-promoting cytokines that preferentially 
activate STAT1 (e.g. IFNs) or STAT4 (e.g. IL-12). This will require further study. Notably, despite 
its elevated expression in the colons of recipients of IL-6Ra-deficient Th17 cells, IL-21, which 
also activates STAT3 and has been implicated as an autocrine factor for Th17 cells (8, 68), was 
also unable to compensate for deficiency of IL-6 signaling in maintenance of the Th17 program. 
The basis for the developmentally-linked shift in STAT activation by the IL-6 receptor and 
insufficiency of autocrine IL-21 to substitute for IL-6 signaling will also require further study. In 
any case, collectively, these findings suggest that the local balance of IL-6 and IL-23 is critical in 
sustaining or destabilizing the Th17 program, resulting a protective versus pathogenic Th17 
response. 
The finding of a critical requirement for paracrine IL-6 in both the induction and maintenance 
of Th17 cells draws a further parallel between Th17 cells and Treg cells (62). Treg cells require 
IL-2 for both their development and maintenance (69), but are unable to produce IL-2 themselves. 
Instead, they are thought to rely on production of IL-2 by activated naive or other effector T cells 
(69), akin to the reliance of Th17 cells on IL-6 produced by innate immune cells. For both lineages, 
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the dependence on a single cytokine as both developmental inducer and maintenance factor renders 
them particularly susceptible to lineage instability. Moreover, as these two cytokines are cross-
inhibitory—IL-6 promotes the development of Th17 cells and inhibits Tregs, while IL-2 promotes 
the development of Tregs and inhibits Th17 cells—this suggests that competition for their 
respective inductive/maintenance cytokine is a major contributor to Th17 versus Treg pool size 
both at homeostasis and during the emergence and subsidence of an antigen-driven inflammatory 
response. This is of particular importance in intestinal tissues, which are enriched in both Th17 
and Treg cells and are subject to ongoing antigenic stimulation from the intestinal microbiome 
(70). In view of the current data that implicate importance of the balance of these cytokines in 
controlling Th17–Treg cell balance during both an evolving and waning antigenic response, it will 
be important to better define the precise sources and dynamics of IL-2 and IL-6 production.  
The relative contribution of Th17 and Th1 cells to immune-mediated diseases has been an area 
of considerable interest. Early seminal studies identified a definitive link between Th1 cells and 
colitis (47, 71), whereas subsequent studies established an essential role for the IL-23–Th17 axis 
in disease pathogenesis (15, 72). A recent study from our group reconciled these findings by 
demonstrating that Th1-like cells, which derive from Th17 precursors contingent on intact IL-23-
induced STAT4 activation and T-bet expression, were critical for colitis development (73). A 
notable feature of our current findings is that IL-6Ra-deficient Th17 cells more readily transitioned 
to IFN-g–producing Th1 cells in vitro yet failed to cause colitis in vivo. Although this appears to 
contradict a requirement for Th1 cells in the pathogenesis of IBD, our previous studies showed 
that Th17 cells assisted the development and/or survival of pathogenic Th1 cells that were unable 
to drive disease on their own (73). While the basis for Th17-mediated support for de novo Th1 
development remains to be defined, a trivial explanation for the observed lack of disease may be 
that the rapid loss of Th17 cells unable to receive IL-6 signaling resulted in an inadequate number 
of Th17 precursors to give rise to sufficient Th1-like cells or promote their de novo development. 
In light of a critical role for ongoing, classic IL-6 signaling in Th17 maintenance, a more 
detailed understanding of the dynamics of IL-6Ra and gp130 expression by Th17 cell populations 
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is needed, as is a better understanding of factors regulating the local concentrations of sIL-6Ra, 
IL-6 and sgp130 in specific tissue microenvironments such as the intestines. While we and others 
have found that IL-6Ra and gp130 are downregulated upon T cell activation (31), the mechanisms 
are different. IL-6Ra appears to be downregulated primarily by cleavage of the extracellular 
domain by the metalloproteinases ADAM10 and ADAM17 in humans (74), or only ADAM 10 in 
mice (75), which would appear to favor a shift from classic to trans IL-6 signaling in developing 
Th17 cells. Surface expression of gp130 is downregulated by internalization, alternative splicing 
of the encoding mRNA to favor the secreted form, and/or other unidentified mechanisms (31). 
While IL-2 signaling has been shown to inhibit expression of Il6ra and Il6st (gp130)(76), little 
else is known about conditions that promote retention or re-expression of IL-6Ra and gp130 by T 
cells, which now appear to be key in determining which cells are competent to retain the Th17 
program and by what mode of IL-6R signaling. Although IL-6 trans-signaling was intact and 
comparable in WT and IL-6Ra-deficient T cells recovered from colitic mice, it was substantially 
diminished, reflecting diminished gp130 expression and/or signaling competency. This impacted 
classic signaling in WT cells as well and suggests that mechanisms controlling the expression of 
gp130 by effector T cells are limiting for Th17 maintenance—irrespective of the expression of IL-
6Ra and the local balance of free versus sIL-6Ra-bound IL-6.  
Although IL-6 trans-signaling was fully sufficient to differentiate Th17 cells in vitro, it was 
insufficient for either Th17 development or maintenance in vivo, despite elevated sIL-6Ra. The 
reasons for this are unclear, but are unlikely to involve complete buffering by sgp130, as sIL-6Ra 
was in substantial excess in colitic mice. Rather, competition from intestinal innate, epithelial and 
stromal cells, all of which can express gp130 and can signal in trans, appeared to prevent IL-6 
trans-signaling in Th17 cells. At least in the colon, a high IL-6–sIL-6Ra ratio due to high local 
production of IL-6 favored sufficiently high concentrations of free IL-6 to enable classic signaling 
to the relatively small percentage of T cells co-expressing membrane bound IL-6Ra and gp130. 
Interestingly, the stoichiometry of IL-6–IL-6Ra was comparable in both the homeostatic and 
inflamed intestines, consistent with a dominant role for classic signaling in Th17 maintenance in 
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this tissue both at baseline and in the diseased state. Whether this is a common feature of mucosal 
and non-mucosal barrier tissues is unknown.  
An association between polymorphisms in the IL6RA gene and susceptibility to both RA and 
IBD have been found (77, 78). The IL6RA variant rs2228145, which leads to increased proteolytic 
cleavage of IL-6Ra and thus a reduction in membrane-bound IL-6Ra in favor of increased serum 
levels (79) is associated with reduced risk of both RA (77) and IBD (78). Although the mechanism 
of protection remains to be characterized, it is possible that it involves both increased buffering of 
free IL-6 as well as reduced expression of cell surface IL-6Ra, such that classic signaling required 
for Th17 development, and thus disease induction, is impaired. Given the findings herein, it is 
possible that this variant also compromises the maintenance of Th17 cells.  
Our finding that ongoing IL-6 signaling is required for Th17 maintenance has implications for 
therapeutics that target Th17-mediated diseases. In systemic Th17-related autoimmune diseases 
such as rheumatoid arthritis, juvenile idiopathic arthritis, and systemic sclerosis, treatment with 
biologics that inhibit IL-6 is an effective or promising therapy (80-82). This is in contrast to tissue-
specific immune-mediated diseases, including IBD, where therapies that inhibit IL-6 signaling 
have not gained clinical use despite evidence that antibodies targeting IL-6 or IL-6Ra may have 
efficacy (83). Given that IL-17A- and IL-22-producing Th17 cells appear to be protective rather 
than pathogenic in the intestines (84), persistent classic IL-6 receptor signaling that sustains 
intestinal Th17 responses may enhance barrier function to restrain disease. This is in line with the 
view that classic and trans-signaling promote anti- and pro-inflammatory responses, respectively 
(85), and suggests that inhibiting classic signaling and thus the protective effects of IL-6 may 
exacerbate disease. Given that IL-6 can amplify inflammation-induced injury to a variety of cells 
and tissues, it remains a valid therapeutic target (31), although it may be important to selectively 
target the pro-inflammatory effects of IL-6 while sparing its protective effects. The development 
of inhibitors that specifically target trans-signaling by inhibiting the docking of the IL-6–IL-6Ra 
complex to gp130 may offer a clinical advantage in selectively targeting the deleterious effects of 
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IL-6 without affecting the more beneficial effects, including the maintenance of protective Th17 
cells.  
 
Materials and Methods 
Study Design 
This study was designed to investigate whether ongoing IL-6 is required for Th17 function, and 
whether classical or trans signaling was more important for maintenance of Th17 cells. 
Experiments consisted of analyzing T cell populations in the inflamed intestines of 
immunodeficient recipients as part of two established T cell transfer models of colitis. All animals 
were bred and maintained in accordance with institutional animal care and use committee 
regulations.  Littermate comparisons were used for all experiments where possible. Gender and 
aged matched male and female mice were used, and animals were randomly assigned into different 
groups.  Group sizes were the minimum required to detect statistically significant differences based 
on previous experience. Experiments were not blinded to investigators, but histopathological 
samples were blinded prior to scoring. All experiments were replicated as presented in the figure 
legends. 
 
Mice 
The following mice were purchased from the Jackson Laboratories: C57BL/6.CD45.1, Il6-/-, 
B6.FVB-Tg(EIIaCre), and Rag1-/-. The generation of Il17fThy1.1/Thy1.1 reporter mice has been described 
previously (19). Il17fThy1.1 mice were crossed to B6.CD45.1 to create Il17fThy1.1(CD45.1). Il6rafl/fl mice 
were a gift from A. Drew (Univ. of Cincinnati) and were crossed with EIIaCre mice to generate Il6ra-
/-. Where indicated, crosses between Il17fThy1.1/Thy1.1 reporter mice and individual knockout mice were 
made in our facility to generate mice homozygous for Il17fThy1.1 and respective gene deletion alleles 
(eg. Il6ra-/-). All mice were on a C57BL/6 background.  
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CD4 T cell preparation and culture 
CD4+ T cells were purified from pooled spleen and lymph nodes by Dynabeads Mouse CD4, 
followed by DETACHaBEAD Mouse CD4, according to the manufacturer’s instructions 
(ThermoFisher). Naïve CD4+ CD62L+ CD25- T cells were obtained by FACS sorting. CD4+ T cells 
were cultured at a ratio of 1:5 with irradiated splenic feeder cells (or, where noted, Dynabeads T-
Activator CD3/CD28 beads (ThermoFisher)) for 7 d in RPMI containing 10% FBS, 100 IU/mL 
penicillin, 100 µg/mL streptomycin, 1 µM sodium pyruvate, 1x non-essential amino acids, 2.5 µM 
b-mercaptoethanol, and 2 µM L-glutamine (R10 medium). Cells were stimulated with 2.5 µg/mL 
anti-CD3 (clone 145-11), and for Th17 polarizations were supplemented with 2.5 ng/mL rhTGF-
b1 (R&D systems), 10 ng/mL rmIL-6 (R&D systems) or 10 ng/mL hyper-IL-6 (S. Jones, Cardiff 
University), 10 µg/mL anti-IFN-g (clone XMG1.2), and 10 ug/mL anti-IL-4 (clone 11B11). In 
restimulation cultures, viable T cells were recovered on day 7 of initial cultures and activated with 
fresh splenic feeders or CD3/CD28 activator beads, cytokines and antibody mixtures as indicated. 
Unless otherwise noted, rmIL-23 or rmIL-12 (R&D systems) were added at 20 ng/mL and 2.5 
ng/ml respectively. 
 
CD4 adoptive transfer model of colitis 
CD4 cells were cultured under Th17 polarizing conditions for 7 d. Viable cells were recovered 
(Ficoll) and Thy1.1+ cells were isolated by magnetic sorting (Miltenyi Biotec). A total of 4 x 105 
Thy1.1+ Th17 cells were injected i.p into age and sex matched Rag1-/- recipients. For co-transfer 
experiments, 2 x 105 each of WT and Il6ra-/- Th17 cells were transferred. For the naïve CD4 transfer 
model, CD4+ CD45RBHi cells were FACS sorted from pooled spleen and lymph nodes and a total 
of 4 x 105 cells were injected into age matched Rag1-/- recipients. Mice were monitored regularly 
for signs of disease and weighed weekly. At 4 or 8 weeks after transfer, mice were sacrificed and 
MLNs and colons were recovered. Colons were cut longitudinally, and small lengths of tissue were 
obtained from the proximal, middle and distal portions of the colon, fixed in 10% formalin, and 
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processed for histopathological analyses. Samples were scored by a pathologist in a blinded 
fashion as previously described (86). 
 
Isolation of colonic lymphocytes 
Lamina propria lymphocytes from the colon (CLP) were isolated as described previously(86). 
Briefly, colons were cut longitudinally, and were cut into 1 cm long strips. Tissues were washed 
in cold 1 x HBSS containing 2% (vol/vol) FBS plus 100 IU/mL penicillin and 100 µg/mL 
streptomycin. After being washed, tissues were digested at 37 C for 45 min with gentle stirring in 
R10 medium containing Collagenase D (100 U/mL) and DNase I (20 mg/mL) (Sigma). Lamina 
propria lymphocytes were purified on a 40%/75% (vol/vol) Percoll gradient by centrifugation for 
20 min at 25 °C. 
 
Flow cytometric analysis 
Where indicated, CD4+ cells were stimulated with PMA (50 ng/mL; Sigma) and Ionomycin (750 
ng/mL; EMD Millipore) for 5 h in the presence of GolgiPlug (BD Biosciences). Intracellular 
staining was performed as previously described(86). LIVE/DEAD Fixable near-IR Dead Cell Stain 
(Invitrogen) was used to exclude dead cells. Staining of CD4+ T cells was performed with 
antibodies to CD4 (RM4-5), IL-6Ra (D7715A7), IL-17A (TC11-18H10), TCR-b (H57-597) and 
Foxp3 (FJK-16s) from BD Biosciences, IFN-g (XMG1.2), TCR-b (H57-597), gp130 (KGP130), 
and Thy1.1 (His51) from eBioscience, and Thy1.1 (OX-7) from Biolegend. For apoptosis analysis, 
Annexin V and Propidium Iodide staining was performed using an Annexin V Apoptosis Detectin 
Kit (eBioscience) according to manufacturer’s instructions. Samples were acquired on an LSRII 
or Attune NxT flow cytometer and data were analyzed with FlowJo software (Tree Star).  
 
Phospho-STAT staining 
CD4+ T cells from in vitro cultures or MLN cells from recipient Rag1-/- mice were rested for 4 h at 
37 °C in RPMI, then stimulated for 15 min with 0.95 nM IL-6 or HDS. Cells were fixed for 15 
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min at 37 °C with 3% paraformaldehyde (PFA), then washed and permeabilized for 30 min at 4 
°C with 90% methanol. Following two washes, cells were stained for 1 h at room temp with 
antibodies against CD4 (clone RM4-5), pSTAT3 (Y705; clone 4/P-STAT3) and pSTAT1 (Y701; 
clone 4a), all from BD Biosciences. 
 
BrdU staining 
Where noted, CD4+ T cell recipient Rag1-/- mice were fed with 1 mg/mL Bromodeoxyuridine 
(BrdU; Sigma) in tap water with 1% sucrose (w/vol) for 7 d prior to sacrifice. At 1 and 4 weeks 
after transfer, CD4+ cells from spleen, MLN and CLP were harvested and BrdU was detected using 
the BrdU Flow Kit (BD Biosciences) according to manufacturer’s instructions. CD4+ cells were 
co-stained with CD4 (RM4-5), LIVE/DEAD Fixable near-IR Dead Cell Stain, TCR-b (H57-597) 
and Ki67 (eBioscience, SolA15). 
 
Measurement of IL-6, sIL6Ra, sgp130, and other analytes 
Blood was collected from mice upon euthanasia, and serum obtained by centrifugation. For colon 
explant cultures, colon tissue was flushed, cut into three equal sections and then opened 
longitudinally. Individual tissue segments were minced and placed in 0.4 ml of R10 medium for 2 
d, then supernatant collected by centrifugation. Cytokines and other analytes were measured by 
Milliplex assay (Millipore) following manufacturer’s instructions. 
 
Immunohistology 
For immunostaining experiments, colons were fixed in 2% (vol/vol) PFA for 2 h at room 
temperature, washed in PBS, and then set overnight at 4 ºC in 20% (wt/vol) sucrose solution. 
Tissue was then rinsed in PBS, cut into equal segments, embedded in O.C.T. (Tissue-Tek), and 
snap frozen. Tissue sections (6-8 µm) were stained with biotinylated anti-CD45.1 (clone A20, 
eBioscience) followed by Streptavidin-Alexa Fluor 488 (Invitrogen), APC-conjugated anti-
EpCAM1 (G8.8, eBioscience), and Alexa Fluor 594-conjugated anti-CD3 (17A2, eBioscience) 
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followed by donkey anti-goat IgG Alexa Fluor 594 to amplify the signal. Images were obtained 
using a Nikon A1R confocal microscope and processed with Nikon Elements software. 
 
RNA-seq analysis 
Adaptors were trimmed and aberrant reads were removed using TrimGalore (version 0.4.5). The 
quality controlled reads were mapped onto the mouse genome build GRCm38 
(ENSEMBL.mus_musculus.release-75)(87) using STAR (version 2.5.3)(88). BAM files were 
sorted using SAMtools (version 0.1.18)(89), and reads were counted for each gene using HTSeq 
(version 0.7.2)(90). Differential expression analysis was performed using DESeq2 (version 
1.18.1)(91) using R (version 3.4.3). Dispersion shrinkage of fold changes was performed with the 
ASHR algorithm (92). To prepare data for gene set enrichment analysis, results of differential gene 
expression analysis were ranked by signed p-value. Gene lists were ranked by p-value of Wald test 
multiplied by sign of fold-change and analyzed for enrichment of curated query gene sets using 
Fast Gene Set Enrichment Analysis (fgsea, version 1.4.0) with 1 million permutations. Gene set 
enrichment p-values of Normalized Enrichment Scores (NES) were corrected with the Benjamini-
Hochberg procedure. When available, gene sets were made from reported results of transcriptome 
analysis. However, for many published data sets, only raw data were available, and gene sets were 
created using in-house scripts. Query gene sets were created from publicly available data. Raw 
data was obtained from the gene expression omnibus (93). Bulk RNA-seq data was analyzed as 
described above and gene sets were made by selecting the top 250 up and down regulated genes 
by p-value with a fold change of at least 1.5. Microarray data was analyzed using the limma R 
package (94). The functions model.matrix and lmFit were used to create and fit linear models, 
respectively. Due to the increased noise in microarray data, the top 125 up and down regulated 
genes were selected by p-value with a fold change of at least 1.5 to create gene sets. All query gene 
sets used are available in Supplemental Table 1. 
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The Jaccard indexes were calculated for each leading edge gene set versus all others by dividing 
the number of genes in the intersection by the number of genes in the union of each comparison. 
The resulting matrix underwent dimension reduction by using t-Stochastic Neighbor Embedding 
(t-SNE) as implemented in the R package Rtsne (version 0.13, with settings dim=2, perplexity=5, 
and max_iter = 50,000).  
 
Gene set enrichment analysis 
Gene set enrichment analysis was performed using software from the Broad Institute(95). A pre-
ranked analysis was performed on a gene list ordered by signed p-value using Classic enrichment 
statistic, 10,000 permutations, and meandiv Normalization mode. Th17 and Th1 associated gene 
sets were created from publicly available microarrays (GEO GSE14308)(57). Limma (3.32.8) was 
used to calculate differential expression by comparing Th1 samples to Th17 samples. The top 250 
genes by most significant adjusted p-value were separated by fold change. Those with a log2 
transformed fold change greater than zero generated the Th1 gene set, those with fold changes less 
than zero generated the Th17 gene set. Hallmark gene sets were obtained from the MSigDB (96). 
Heatmaps were created using R 3.0.1 and the function heatmap.2 from the ggplot2 package (97). 
 
Retrovirus production and CD4+ T cell transduction 
GFP and RORgt GFP retroviruses were produced by transfecting Platinum-E  packaging cells (Cell 
Biolabs) with pMIG (Addgene #9044) or MIGR-RORgt (Addgene #24069) retroviral plasmids 
using Lipofectamine 2000 (ThermoFisher), and collecting supernatant 24 and 48 hours later.  
To transduce Th17 cells, FACS-sorted naïve CD4+ T cells from Il17fThy1.1 mice were cultured in R10 
medium with Dynabeads Mouse T-activator CD3/CD28 beads (ThermoFisher) at a ratio of 5 beads 
per CD4+ cell. After 24 hours, cells were spin infected with retrovirus containing media for 90 min 
(2500 rpm, 30 ºC). Cells were then washed with R10 medium and cultured for a further 4 d under 
Th17 polarizing conditions. For transfers, CD4+ Thy1.1+ GFP+ cells were FACS sorted and injected 
i.p into age and sex matched Rag1-/- recipients.  
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Real-time PCR 
Congenically marked CD4+ TCR-b+ cells were sorted from the CLP of Rag1-/- recipients. Total RNA 
was isolated using an miRNeasy Isolation kit (Qiagen) according to manufacturer’s instructions. 
cDNA was synthesized with the iScript Reverse Transcription Supermix (BioRad), and real-time 
PCR was performed with SsoAdvanced Universal Probes Supermix or SsoAdvanced Universal 
SYBR Green Supermix (BioRad) for 35-40 cycles. Reactions were run in duplicate and normalized 
to B2m.  
 
Statistical analysis 
Statistical significance was calculated using Prism software (GraphPad). The nonparametric two-
tailed Mann Whitney test or Kruskal Wallis test was used to determine significance for pathology 
data, all other data was analyzed using unpaired two-tailed Student’s t-test or one-way ANOVA 
as appropriate. All P values ≤ 0.05 were considered significant. 
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Figures  
Fig. 1. Naïve CD4+ T cells require IL-6 for development and colitis pathogenesis. FACS sorted 
CD4+ CD45RBHi T cells isolated from WT and Il6ra-/- mice were transferred into Rag1-/- recipients 
(4 x 105/mouse)(n = 5 per group) and analyzed for colitis 8 weeks after transfer. (A) Weight loss 
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expressed as a percentage of starting weight (mean ± SEM). * P < 0.05, ** P < 0.01. (B) Total 
numbers of CD4+ T cells recovered from the CLP of colitic mice (mean + SEM). ** P = 0.0044. 
(C) Histological scores (mean + SEM). ** P = 0.005 (E) Representative H&E stained sections of 
colon from recipients of WT (upper panel) or Il6ra-/- CD4+ T cells. H&E stain; original 
magnification 10x; scale bars 100 µm (E) Representative FACS plots showing Foxp3 expression 
in CLP CD4+ T cells ex vivo from WT or Il6ra-/- recipients after development of colitis. (F) Relative 
frequencies (upper) and total numbers (lower) of Foxp3+ CD4+ T cells from the CLP (mean ± SEM). 
P = 0.1724 (upper), P = 0.054 (lower) (G) Representative FACS plots showing IL-17A and IFN-
g in CLP CD4+ T cells ex vivo after development of colitis. (H) Relative frequencies (upper) and 
total numbers (lower) of IL-17A+, IL-17A+IFN- g +, and IFN- g + CD4+ T cells in the CLP of colitic 
mice (mean ± SEM). * P = 0.0268, * P = 0.0121, P = 0.0803 (upper IL-17A+, IL-17A+IFN- g +, and 
IFN- g + CD4+ T cells); ** P = 0.0023, *** P = 0.0008, * P = 0.0191 (lower IL-17A+, IL-17A+IFN-
 g +, and IFN- g + CD4+ T cells) Data are representative of at least three independent experiments (A, 
D-H; n = 5 per group), or pooled from two independent experiments (B, C; n = 10 per group). P 
values; two-way ANOVA with Bonferroni post-test (a) or unpaired two-tailed Student’s t-test (B-
C, F, H).  
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Fig. 2. Maintenance and pathogenesis of Th17 cells is dependent on persistent IL-6 signaling. 
CD4+ T cells from Il17fThy1.1 mice were cultured with splenic feeder cells under Th17 polarizing 
conditions (2.5 µg/ml anti-CD3, 2.5 ng/ml TGF-b, 10 ng/ml IL-6, 10 µg/ml anti-IFN-g, 10 µg/ml 
anti-IL-4) for 7 d. (A) Expression of IL-17A, IFN-g and Thy1.1 in a fraction of in vitro cultured 
CD4+ T cells after PMA/Ionomycin stimulation for 5 h in the presence of monensin. (B) Thy1.1 
expression in CD4+ T cells after purification of Thy1.1+ (IL-17F+) Th17 cells. 4 x 105 cells Th17 
cells per mouse were transferred into Rag1-/- (n = 4) or Il6–/–. Rag1-/- (n = 8) mice. Four weeks after 
transfer, mice were analyzed for development of colitis. (C) Histological scores (mean + SEM). * 
P = 0.0264. (D) Representative H&E stained sections of colon from Rag1-/- (left) or Il6-/-. Rag1-/- 
(right) recipients of WT Th17 cells. H&E stain; original magnification 10x; scale bars 100 µm. 
(E) Representative FACS plots showing IL-17A and IFN-g in CLP CD4+ T cells ex vivo. (F) 
Relative frequencies (upper) and total numbers (lower) of IL-17A+, IL-17A+ IFN-g+, and IFN-g+ 
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CD4+ T cells in the CLP of colitic mice (mean ± SEM). ** P = 0.0099, * P = 0.0302. Data are 
representative of at least two independent experiments. P values; unpaired two-tailed Mann-
Whitney test (C) or unpaired two-tailed Student’s t-test (F). 
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Fig. 3. Classic IL-6 signaling is required for maintenance of pathogenic Th17 cells. (A) Model 
of classic vs. trans IL-6 signaling in Th17 development. Early Th17 development is mediated by 
classic IL-6 signaling involving membrane IL-6Ra associating with gp130 (left). After activation, 
IL-6Ra is cleaved by ADAM proteases (middle), and late development is believed to be mediated 
by trans-signaling (right), where shed soluble IL-6Ra (sIL-6Ra) complexes with IL-6 and binds 
gp130 to induce signaling. (B) CD4+ T cells from Il17fThy1.1 (WT) and Il6ra-/-.Il17fThy1.1 (Il6ra-/-) were 
cultured with irradiated splenic feeder cells under Th17 polarizing conditions (2.5 µg/ml anti-CD3, 
2.5 ng/ml TGF-b, 10 µg/ml anti-IFN-g, 10 µg/ml anti-IL-4) for 7 d with 10 ng/ml IL-6 or 10 ng/ml 
recombinant IL-6-sIL6Ra (HDS). A fraction of cells was analyzed for expression of CD4 and 
intracellular IL-17A and IFN-g after PMA/Ionomycin stimulation for 5 hr in the presence of 
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monensin. FACS plots are gated on CD4+ cells. (C) WT (IL-6), WT (HDS) and Il6ra-/- Thy1.1+ Th17 
cells obtained in (B) were transferred into Rag1-/- mice (4 x 105/mouse). Histological scores were 
analyzed four weeks after transfer (mean + SEM)(WT (IL-6) n = 8, WT (HDS) n = 13, Il6ra-/- n = 
12). * P = 0.0305. (D) Serum sIL-6Ra levels from naïve Rag1-/- mice as well as colitic recipients 
of WT (hIL-6) and Il6ra-/- Th17 cells at 4 weeks post transfer (n = 5 per group) were quantified by 
Milliplex assay (mean + SEM). * P <0.05. (E) Representative FACS plots showing IL-17A and 
IFN-g in CLP CD4+ T cells ex vivo. (F) Representative FACS plots showing Foxp3 in CLP CD4+ 
T cells ex vivo. (G) Relative frequencies (upper) and total numbers (lower) of IL-17A+, IL-17A+ 
IFN-g+, and IFN-g+ CD4+ T cells in the CLP of colitic mice (mean ± SEM)(n = 5 per group). (H) 
Relative frequencies and (I) total numbers of CD4+ Foxp3+ T cells in the CLP of colitic mice (mean 
+/- SEM). Data are pooled from (C) or representative of (E – I) three independent experiments. P 
values; non parametric Kruskal-Wallis with Dunn’s post comparison test (C), one-way ANOVA 
with Bonferroni post test (D) or Tukey’s Multiple Comparison test (G – I). 
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Fig. 4. Loss of Th17 phenotype in IL-6Ra-deficient Th17 cells is not rescued by co-transfer 
of WT Th17 cells. (A) Experimental schematic. CD4+ T cells from Il17fThy1.1CD45.1 (WT) and Il6ra-
/-.Il17fThy1.1 (Il6ra-/-) were cultured with irradiated splenic feeder cells under Th17 polarizing 
conditions for 7 d with 10 ng/ml HDS. Thy1.1+ Th17 cells were transferred separately (4 x 
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105/mouse) or together (2 x 105 each/mouse) into Rag1-/- recipients (WT n = 4, Il6ra-/- n = 4, WT + 
Il6ra-/- n = 5, WT + Il6ra-/- (2 wks) n = 5). (B) Histological scores were analyzed four weeks after 
transfer (mean + SEM). * P < 0.05 (C) Relative frequencies (upper) and total numbers (lower) of 
IL-17A+, IL-17A+ IFN-g+, and IFN-g+ CD4+ T cells in the CLP of colitic mice (mean ± SEM). * P < 
0.05, ** P < 0.01, *** P < 0.001. (D) Representative FACS plots showing IL-17A and IFN-g in 
CLP CD4+ T cells from recipients of single or co-transfers ex vivo after development of colitis. (E-
F) Levels of sIL-6Ra, sgp130 and IL-6 in colon explants and serum of naïve Rag1-/- mice as well 
as colitic recipients of single or co-transfer Th17 cells were quantified by Milliplex assay. Molar 
ratio of IL-6–IL-6Ra (E) and IL-6Ra–sgp130 (F) in colon explants (squares) and serum (circles) 
from colitic mice are shown. (G) Colon tissue from WT + Il6ra-/- Th17 co-transfers were stained 
with anti-EpCAM1 (blue), anti-CD45.1 (green) and anti-CD3 (red). Left panel shows anti-CD45.1 
(WT), middle panel shows anti-CD3 (total T cells), right panel shows merged image (red arrows, 
Il6ra-/- CD4+ T cells ; green arrows, WT CD4+ T cells). Scale bars 20 µm. (H) Quantification of WT 
and Il6ra-/- CD4+ T cells from (G). Data are representative of three independent experiments. P 
values; non parametric Kruskal-Wallis with Dunn’s post comparison test (B), one-way ANOVA 
with Bonferroni post test (C). 
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Fig. 5. IL-6Ra-deficient Th17 cells are responsive to trans-signaling ex vivo. Thy1.1+ Th17 
cells from Il17fThy1.1CD45.1 (WT) and Il6ra-/-.Il17fThy1.1 (Il6ra-/-) were adoptively transferred together (2 
x 105 each/mouse) into Rag1-/- recipients (n = 4 mice). Four weeks after transfer, CD4+ cells from 
the MLN of recipient mice or naïve CD4+ cells from the MLN of WT mice were stimulated with 
equimolar concentrations of IL-6 or HDS (0.95nM) for 15 min. (A) Representative FACS plots 
showing pSTAT3 (Y705) in MLN CD4+ T cells from naïve or colitic mice. (B) Representative 
FACS plots showing pSTAT1 (Y701) in MLN CD4+ T cells from naïve or colitic mice. (C). 
Relative frequencies of pSTAT3+ (upper) and pSTAT1+ CD4+ T cells (lower) in the MLN of colitic 
mice (mean + SEM). * P < 0.05, ** P < 0.01. Data are representative of two independent 
experiments. P values; two-way ANOVA with Bonferroni post-test (C). 
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Fig. 6. IL-6 is required to maintain a Th17 gene program in vivo. (A) Experimental schematic. 
Thy1.1+ Th17 cells from Il17fThy1.1CD45.1 (WT) and Il6ra-/-.Il17fThy1.1 (Il6ra-/-) were adoptively 
transferred together (2 x 105 each/mouse) into Rag1-/- recipients (n = 4). Four weeks after transfer, 
congenically marked CD4+ cells from the CLP of recipient mice were isolated and gene expression 
was assessed by RNA-seq. (B) Recovery of CLP CD4+ cells from Rag1-/- recipients of WT and 
Il6ra-/- Th17 cells (mean ± SEM). (C) Total number of CLP CD4+ T cells recovered from Rag1-/- 
recipients (mean + SEM). (D) MA plot displaying differentially expressed genes in WT (lower) 
and Il6ra-/- (upper) CD4+ T cells ex vivo. Red circles indicate genes with false discovery rate (FDR) 
<0.05. (E) Barcode plots of gene set enrichment results obtained using a set of genes previously 
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reported to be differentially expressed between Th17 cells (left) or Th1 cells (right) (data from 
GSE 14308) (NES, normalized enrichment score). (F) Expression of representative Th1 and Th17 
cell associated genes identified by gene set enrichment in (E) are depicted by heat map with z-
scored expression values. (G) Barcode plots of gene set enrichment results obtained using a set of 
genes previously reported to be regulated by Rorc in Th17 cells (GSE 40918). (H) Expression of 
representative genes identified by gene set enrichment in (G) are depicted by heat map with z-
scored expression values. (I) Barcode plots of gene set enrichment results obtained using a set of 
genes previously reported to be regulated by Stat3 in Th17 cells (GSE 40918) (J). Expression of 
representative genes identified by gene set enrichment in (I) are depicted by heat map with z-
scored expression values. Data are from two independent experiments.  
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Fig. 7. Enforced RORgt expression represses transition to Th1-like cells by IL-6Ra-deficient 
Th17 precursors in vivo. (A) CD4+ T cells from Il17fThy1.1 CD45.1 (WT) and Il6ra-/-.Il17fThy1.1 (Il6ra-/-) 
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were cultured under Th17 polarizing conditions (2.5 ng/ml TGF-b, 10 µg/ml anti-IFN-g, 10 µg/ml 
anti-IL-4, 10 ng/ml HDS) with CD3/CD28 expander beads (ThermoFisher) and transduced with 
retroviruses encoding GFP alone (pMIG) or GFP with RORgt (pMIG- RORgt). FACS plots show 
GFP and Thy1.1 expression on D6 and are gated on CD4+ T cells. (B) Th17p were stained 
intracellularly for IL-17A and IFN-g after PMA/Ionomycin activation for 5 h in the presence of 
monensin. FACS plots are gated on CD4+ GFP+ Thy1.1+ cells. (C) GFP+ Thy1.1+ Th17 cells from 
(A) were FACS purified and transferred together (2 x 105 each/mouse) into Rag1-/- recipients (WT 
pMIG + Il6ra-/- pMIG n = 7, WT pMIG + Il6ra-/- pMIG-RORgt n = 7). Histological scores were 
analyzed three weeks after transfer (mean + SEM). (D) Representative FACS plots showing IL-
17A and IFN-g in CLP CD4+ T cells from recipients of co-transfers ex vivo after development of 
colitis. (E) Relative frequencies of IL-17A+, IL-17A+ IFN-g+, and IFN-g+ CD4+ T cells in the CLP of 
colitic mice (mean ± SEM). * P < 0.05, ** P < 0.01, *** P < 0.001. (F) Representative H&E 
stained sections of colon from recipients of WT pMIG + Il6ra-/- pMIG or WT pMIG + Il6ra-/- pMIG-
RORgt CD4+ T cells. H&E stain; original magnification 10x; scale bars 100 µm. (G) RNA isolated 
from FACS purified WT and Il6ra-/- CLP CD4+ T cells from co-transfer recipients was analyzed ex 
vivo by qPCR for expression of Il17a, Il17f, Rorc, Tbx21, Il12rb2 and Il23r (mean + SEM of three 
biological replicates). * P < 0.05, ** P < 0.01. Data are representative of three experiments. P 
values; one-way ANOVA with Tukey’s multiple comparison test (G) or one-way ANOVA with 
Bonferroni post test (E) . 
 
 
 
Supplementary Materials: 
Supplementary Fig. 1. Classical IL-6 signaling is required for development of colitis. 
Supplementary Fig. 2. Innate derived IL-6 is required for Th17 pathogenicity and maintenance. 
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Supplementary Fig. 3. Classical IL-6 signaling is required for maintenance of Th17 cells. 
Supplementary Fig. 4. Co-transfer of Il6ra-/- with WT Th17 cells is unable to rescue their 
phenotype. 
Supplementary Fig. 5. Co-transfer of Il6ra-/- with WT Th17 cells is unable to rescue their Th17 
phenotype. 
Supplementary Fig. 6. IL-6Ra and gp130 expression on Th17 cells ex vivo. 
Supplementary Fig. 7. Il6ra-/- Th17 cells lose their Th17 gene expression signature in vivo. 
Supplementary Table 1. Full gene sets used for GSEA analysis. 
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Supplemental Figures 
 
Supplementary Fig. 1. Classical IL-6 signaling is required for development of colitis. FACS 
sorted CD4+ CD45RBHi T cells isolated from WT and Il6ra-/- mice were transferred into Rag1-/- 
recipients (4 x 105 per mouse)(WT n = 5 per group, Il6ra-/- n = 6 per group) and analyzed for colitis 
8 weeks after transfer. (A) Representative FACS plots showing IL-17A and IFN-g in MLN CD4+ 
T cells ex vivo after development of colitis. (B) Representative FACS plots showing Foxp3 
expression in MLN CD4+ T cells ex vivo from WT or Il6ra-/- recipients after development of colitis. 
(C) Relative frequencies (upper) and total numbers (lower) of IL-17A+, IL-17A+IFN-g+, and IFN-g+ 
CD4+ T cells in the MLN of colitic mice (mean ± SEM). *** P <0.0001, *** P <0.0001, ** P = 
0.0045 (upper IL-17A+, IL-17A+IFN- g +, and IFN- g + CD4+ T cells). ** P = 0.002, ** P = 0.0046, P 
= 0.3380 (lower IL-17A+, IL-17A+IFN- g +, and IFN- g + CD4+ T cells) (D) Relative frequencies 
(upper) and total numbers (lower) of Foxp3+ CD4+ T cells from the MLN (mean ± SEM). P = 
0.2940 (upper), P = 0.0887 (lower). P values; unpaired two-tailed Student’s t-test (C - D). 
Harbour et al. 
 
 
Supplementary Fig. 2. Innate derived IL-6 is required for Th17 pathogenicity and 
maintenance. (A) Total numbers of CD4+ T cells recovered from the CLP of Rag1-/- (n = 4) or Il6-
/-.Rag1-/- (n = 8) recipients (mean + SEM). (B-C) Relative frequencies (B) and total numbers (C) of 
Foxp3+ CD4+ T cells from the CLP of Rag1-/- or Il6-/-.Rag1-/- recipients (mean ± SEM). (D) 
Representative FACS plots showing expression of Annexin V and Propidium Iodide (PI) in CD4+ 
T cells recovered from the CLP of colitic Rag1-/- or Il6-/-.Rag1-/- recipients. (E-F) Relative 
percentages of necrotic (Annexin V+ PI+) (E) and apoptotic (Annexin V+PI+) (F) CD4+ T cells from 
the CLP of colitic Rag1-/- or Il6-/-.Rag1-/- recipients (mean + SEM). 
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Supplementary Fig. 3. Classical IL-6 signaling is required for maintenance of Th17 cells. (A) 
CD4+ T cells from Il17fThy1.1 (WT) and Il6ra-/-. Il17fThy1.1 (Il6ra-/-) were labeled with Cell Trace Violet 
Harbour et al. 
 
(CTV; ThermoFisher) and cultured with irradiated splenic feeder cells under Th17 polarizing 
conditions for 7 d with 10 ng/ml recombinant hIL-6. A fraction of cells were analyzed for 
expression of CD4 and CTV dilution. FACS plots are gated on CD4+ Thy1.1+ Th17 cells. (B). CD4+ 
T cells from Il17fThy1.1 (WT) and Il6ra-/-. Il17fThy1.1 (Il6ra-/-) were cultured with irradiated splenic feeder 
cells under Th17 polarizing conditions with 10 ng/ml IL-6 or 10 ng/ml recombinant IL-6-sIL6Ra 
(HDS) for 7 d. A fraction of cells was analyzed for expression of CD4 and intracellular IL-17A 
and IFN-g after PMA/Ionomycin stimulation for 5 hr in the presence of monensin. FACS plots are 
gated on CD4+ cells. (C) 6 days after culture, Thy1.1+ Th17 precursors were isolated and gene 
expression analyzed by RNA seq. Plot shows PCA analysis of mRNA transcriptome in naïve and 
in vitro Th17 polarized WT (IL-6), WT (HDS) and Il6ra-/- (HDS) CD4+ T cells by RNA-seq 
analysis. Each dot represents an individual mouse. Data are from two independent experiments. 
(D) MA plot displays differentially expressed genes in WT (HDS)(upper) and WT (IL-6)(lower) 
CD4+ T cells ex vivo. Red circles indicate genes with false discovery rate (FDR) <0.05. (E) CD4+ 
T cells from Il17fThy1.1 (WT) and Il6ra-/-. Il17fThy1.1 (Il6ra-/-) were cultured with irradiated splenic feeder 
cells under Th17 polarizing conditions with 10 ng/ml IL-6 or 10 ng/ml recombinant IL-6-sIL6Ra 
(HDS). On day 5, Th17 cells were stimulated with equimolar concentrations of IL-6 or HDS 
(0.95nM) for 15 min. Representative FACS plots show pSTAT3 (Y705) in in vitro polarized Th17 
cells. (F) Fold change of pSTAT3 (Y705) MFI (GeoMean) relative to isotype control (mean + 
SEM) from three independent experiments. * P < 0.05,  one-way ANOVA with Bonferroni post-
test. (G) Colon culture explant supernatants from Rag1-/- recipients of WT or Il6ra-/- Th17 cells (n 
= 3 per group) were assayed for select cytokines by Luminex assay (Millipore) four weeks after 
transfer. Data are expressed as pg/mg/ml tissue (mean + SEM) and represent one of two 
independent experiments.  IL-17A * P = 0.048, IFN-g P = 0.1742, IL-21 * P = 0.0303, IL-17F P 
= 0.1573, IL-22 P = 0.1366, IL-23 * P = 0.0465, IL-12p40 * P = 0.0328, IL-12p70 P = 0.0997. P 
values; unpaired two-tailed Student’s t-test. 
(H) Total number of CD4+ T cells isolated from the CLP of Rag1-/- recipients of WT (IL-6), WT 
(HDS) or Il6ra-/- Th17p cells four weeks after transfer (mean + SEM). (I) Representative H&E 
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stained sections of colon from Rag1-/- recipients of WT (IL-6)(left), WT (HDS)(middle), or Il6ra-
/- Th17p (right) WT Th17 cells. H&E stain; original magnification 10x; scale bars 100 µm. 
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Supplementary Fig. 4. Co-transfer of Il6ra-/- with WT Th17 cells is unable to rescue their 
phenotype. (A) Relative percentage (upper) and total numbers (lower) of CD4+ T cells recovered 
from the CLP of colitic recipients of WT, Il6ra-/- or WT + Il6ra-/- co-transfers of Th17 cells (mean 
+ SEM). (B) Representative FACS plots showing expression of Foxp3 in recovered CD4+ T cells 
from the CLP of colitic  mice. (C) Relative frequencies (upper) and total number (lower) of CD4+ 
Foxp3+ cells in the CLP of colitic recipients of WT, Il6ra-/- or WT + Il6ra-/- Th17 co-transfers (mean 
± SEM). (D) Representative FACS plots showing expression of IL-17A, TNF-a and GM-CSR in 
recovered CD4+ T cells from the CLP of colitic  mice. (E)  Relative percentage of IL-17A+GM-
CSF+, GM-CSF+ (upper), IL-17A+TNF-a+, and TNF-a+ CD4+ T cells in the CLP of colitic mice 
(mean ± SEM). ** P < 0.01 (unpaired two-tailed Student’s t-test). (F-G) Levels of sIL-6Ra, sgp130 
and IL-6 in colon explants (F) and serum (G) of naive Rag1-/- mice as well as colitic recipients of 
single or co-transfer Th17 cells were quantified by Milliplex assay (mean + SEM). Data are 
representative of two independent experiments (WT n = 4, Il6ra-/- n = 4, WT + Il6ra-/- n = 5, WT + 
Il6ra-/- (2 wks) n = 5). * P < 0.05, ** P < 0.01, *** P < 0.001 (one-way ANOVA with Bonferroni 
post-test). 
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Supplementary Fig. 5. Co-transfer of Il6ra-/- with WT Th17 cells is unable to rescue their 
Th17 phenotype. Rag1-/- mice (n = 4 per group) were adoptively transferred with 4 x 105 WT or 
Il6ra-/- Th17 cells or co-transferred with 2 x 105  WT + Il6ra-/- Th17 cells. Recipient mice were fed 
with water containing 1 mg/ml Bromodeoxyuridine (BrdU) for 7 days. (A and C). Representative 
FACS plots show BrdU staining of CD4+ T cells recovered from the spleens (A) and MLN (C) of 
single and co-transfer Th17 cell recipients 7 days after transfer. (B and D) Relative percentage of 
BrdU+ CD4+ cells (upper) and total CD4+ cells (lower) in the spleen (B) and MLN (D) of single and 
co-transfer Th17 recipients 7 days after transfer (mean ± SEM). (E and G) Representative FACS 
plots showing BrdU staining of CD4+ T cells recovered from the CLP (E) and MLN (G) of single 
and co-transfer Th17 cell recipients 4 weeks after transfer. (F and H) Relative percentage of BrdU+ 
CD4+ cells (upper) and total CD4+ cells (lower) in the CLP (F) and MLN (H) of single and co-
transfer Th17 recipients 4 weeks after transfer (mean ± SEM). (I) Relative percentages of CD4+ 
Ki67+ cells in the spleen (left) and MLN (right) of recipient mice 7 days after transfer (mean ± 
SEM). (J) Relative percentages of CD4+ Ki67+ cells in the CLP (left) and MLN (right) of recipient 
mice 4 weeks after transfer (mean ± SEM). (K) Representative H&E stained sections of colon 
from recipients of (left to right) WT,  Il6ra-/-, WT + Il6ra-/- (4 wks)  and WT + Il6ra-/- (2 wks) CD4+ 
T cells. H&E stain; original magnification 10x; scale bars 100 µm. Data are representative of two 
independent experiments. * P < 0.05 (one-way ANOVA with Bonferroni post-test). 
  
Harbour et al. 
 
 
 
Supplementary Fig. 6. IL-6Ra and gp130 expression on Th17 cells ex vivo. (A) Representative 
FACS plots showing IL-6Ra expression in CLP CD4+ T cells ex vivo, 4 weeks after Rag1-/- 
recipients were co-transferred with WT and Il6ra-/- Th17 cells (n = 4 per group). (B) Relative 
percentage (left) and geometric mean fluorescence (right) of CD4+ IL-6Ra+ cells in CLP CD4+ T 
cells ex vivo. *** P <0.0001. (C). Representative FACS plots showing gp130 expression in CLP 
CD4+ T cells ex vivo. (D). Relative percentage (left) and geometric mean fluorescence (right) of 
CD4+ gp130+ cells in CLP CD4+ T cells ex vivo (mean + SEM). Data are representative of two 
independent experiments. P values; unpaired two-tailed Student’s t-test. 
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Supplementary Fig. 7. Il6ra-/- Th17 cells lose their Th17 gene expression signature in vivo. 
(A) Similarity of gene sets calculated by the Jaccard index. Dimensions were reduced to two with 
t-SNE and visualized with a scatterplot. (B) Barcode plots of gene set enrichment results obtained 
using sets of genes previously reported to be regulated by several Th17 transcription factors (GSE 
40918). (C) Barcode plots of gene set enrichment results obtained using a set of genes regulated 
by Il23r in Th17 cell (GSE 58147). (D) Expression of representative genes identified by gene set 
enrichment in (C) are depicted by heat map with z-scored values. Data are from two independent 
experiments. 
 
